Yes, SoC for diabetes care and CVD risk reduction is always evolving.

Ozempic, the injectable form of semaglutide, proved itself to elicit CVD risk reduction in SUSTAIN-6 trial long ago. The trial completed and was published in 2016. This news of supplemental NDA approval for CVD risk reduction for Ozempic is not surprising one bit. 

https://www.novonordisk.com/media/news-details.2232313.html

https://www.nejm.org/doi/full/10.1056/NEJMoa1607141

BTW, semaglutide is a GLP-1 analogue (sometimes referred to as a GLP-1R agonist). This is a completely different drug class than the SGLT2 inhibitors. Others in the GLP1-R agonist class have also shown CVD risk reduction (dulaglutide, liraglutide, albiglutide). 

Also in the Novo news today is that the oral version of semaglutide, Rybelsus, will have its label updated with cardio safety info based on SUSTAIN-6 and the PIONEER 6 trials. However, this oral version still has yet to definitively prove itself to reduce cardiovascular outcomes. This will have to wait for the completion of the ongoing SOUL trial.

Both GLP1-R agonists and SGLT2 inhibitors are the current go to SoC drugs for CVD prevention in diabetics. Both classes were initially approved for glucose control; the CVOTs and expanded label to cover CVD indication came later. Vascepa is also going to be another SoC drug for diabetics w/ elevated TG.

BDAZ